Navigation Links
Lilly Announces New Investment to Further Boost Its Biotechnology Capabilities
Date:6/28/2011

WASHINGTON, June 28, 2011 /PRNewswire/ -- Today at the BIO International Convention, Eli Lilly and Company (NYSE: LLY) announced a multi-million dollar investment to expand its existing biotechnology capabilities. This investment is further fueling research and development of multi-specific therapeutics, in which two or more distinct mechanisms of action are engineered in one molecule with the goal of providing enhanced efficacy with an improved safety profile.

"In many therapeutic areas -- for instance, diabetes and oncology-- one medicine isn't enough for patients to manage their disease," said Tom Bumol, Ph.D., vice president of biotechnology discovery research at Lilly. "With our extensive biologics experience, we can now engineer new therapies where one medicine essentially provides the benefit of two. This could produce real benefits for patients, healthcare professionals and payors."  

Lilly already has several multi-specific therapeutics in preclinical development, including a co-agonist peptide being studied as a potential treatment for diabetes that is anticipated to enter clinical development by the end of this year. Lilly is hiring additional biochemists and biologists to further support its important work in multi-specific therapeutics. These new employees will work at Lilly's biotechnology facilities in Indianapolis and San Diego.

Multi-specific therapeutics are different from combination therapies. With combination therapies, molecules are administered separately to hit two or more targets that contribute to disease. With multi-specific therapeutics, two or more mechanisms of action are literally combined with molecular biology into a single molecule to hit these same targets. Scientists believe that they can design these novel molecules with protein engineering strategies that maximize therapeutic benefit while also minimizing or even remov
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Lilly Declares Third-Quarter 2011 Dividend
2. Lilly for Better Health™ Launches Enhanced Multi-Channel Patient Education Platform
3. Synthes and Lilly Sign Development and Collaboration Agreement
4. U.S. District Court Rules in Favor of Lilly in Amylin Litigation
5. FDA Approves Updates to Lillys Humalog® (insulin lispro injection [rDNA origin]) Label
6. Correction: Lilly Presents Data on Cixutumumab in Five Subtypes of Sarcomas
7. Amylin Pharmaceuticals Obtains Temporary Restraining Order Against Eli Lilly
8. Lilly Comments on Court Ruling in Amylin Litigation
9. Lilly and Investor Group Form New Critical Care Company BioCritica, Sign Xigris License Agreement
10. Study Determined Best Dose and Showed 55 Percent Response Rate With Lilly Anti-BAFF Monoclonal Antibody in Previously-Treated Multiple Myeloma Patients
11. David M. Kendall, M.D., Named Distinguished Medical Fellow at Lilly
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... , Oct. 1, 2014  Dyadic International, ... with patented and proprietary technology used to develop ... bioenergy, bio-based chemicals, biopharmaceuticals, and industrial enzymes industries, ... payment from Abengoa Bioenergy for commercial scale production ... biomass into ethanol, developed under Abengoa,s license agreement ...
(Date:10/1/2014)... NEW YORK , October 1, 2014 ... provider for the medical industries, announced today the expansion of its ... New York City . genae Americas was incorporated in 2011. ... centered in one of the highest concentrations of medical innovation and ... , President at genae Americas. "The expansion of genae from ...
(Date:10/1/2014)... Oct. 1, 2014  Varian Medical Systems (NYSE: ... results for the fourth quarter of fiscal year 2014 ... 22, 2014.  The news release will be followed by ... p.m. PT.  The news release and a link to ... company website at: www.varian.com/investor .  To access the ...
Breaking Medicine Technology:Dyadic International Reports Licensing Payment For Commercial-Scale Production Of C1-Based Cellulase Enzymes 2Dyadic International Reports Licensing Payment For Commercial-Scale Production Of C1-Based Cellulase Enzymes 3genae Opens Offices in New York City 2Varian Medical Systems Schedules Fourth Quarter FY2014 News Release and Conference Call 2
... As part of its ongoing work in the prevention ... Diagnostics is pleased to announce its sponsorship of the ... a kick-off event at Loyola University in Chicago on ... the goal of World MRSA Day is to highlight ...
... 28 Chimerix, Inc., a pharmaceutical company developing orally-available ... and Chief Executive Officer, will present a corporate overview ... 5th, 2010 at 2:00pm PT.  The conference is being ... Mr. Moch will discuss the company,s antiviral ...
Cached Medicine Technology:Roche Diagnostics Supports Fight Against MRSA as a Sponsor of Annual World MRSA Day 2Roche Diagnostics Supports Fight Against MRSA as a Sponsor of Annual World MRSA Day 3Chimerix to Present at 9th Annual BIO Investor Forum 2
(Date:10/1/2014)... study published today in the Journal of the ... than 50 years with moderate or severe chronic knee ... from the University of Melbourne randomly assigned 282 patients ... no acupuncture or sham or pretend laser treatment. ... and acupuncturists blinded to laser and sham (inactive) laser ...
(Date:10/1/2014)... 1, 2014) Despite a policy focus on ... disabilities, this vulnerable population continues to have significant ... The Journal of the American Dental Association , ... Tufts University School of Dental Medicine report on ... at-home oral care provided by caregivers to adults ...
(Date:10/1/2014)... Insuranceragents.info has released a new blog post explaining how ... family members. , Life insurance plans provide important financial ... should always carry a life insurance policy as their ... the family. , Clients can choose from several ... coverage or from a permanent policy. No medical exam ...
(Date:10/1/2014)... Phoseon Technology, the pioneer in developing ... business worldwide. This rapid growth includes increased hiring for ... efforts. The company has experienced average annual growth rates ... this growth to continue in the future as new ... , “We are very pleased that UV ...
(Date:10/1/2014)... new genetic finding from Duke Medicine suggests that some ... might also be hard-wired to gain weight when exposed ... , An estimated 13 percent of people, all of ... knowing this could help them reduce heart disease with ... stress management. , "Genetic susceptibility, psychosocial stress and metabolic ...
Breaking Medicine News(10 mins):Health News:Study finds acupuncture does not improve chronic knee pain 2Health News:To improve oral health of adults with developmental disabilities, support caregivers 2Health News:To improve oral health of adults with developmental disabilities, support caregivers 3Health News:Life Insurance for Families - Clients Can Compare Affordable Rates Online! 2Health News:Phoseon Technology Continues to Drive Growth Worldwide 2Health News:Gene interacts with stress and leads to heart disease in some people 2
... that often deals with changes over many generations have ... A lot, some scientists say. If recent recommendations are implemented, ... entrance and licensing exams, says an international group of doctors ... 26 issue of Proceedings of the National Academy of ...
... is the focus of a $1.27-million grant from the ... researchers working with employees from six Pennsylvania prisons and ... an intervention toolkit for use by staff at any ... to optimize the quality of life for dying patients ...
... Vancouver’s ... meet Matt Lauer when he is in Vancouver to shoot the Today Show during the ... (PRWEB) ... is on a mission to meet Matt Lauer when he is in Vancouver to shoot ...
... , ... Spend More Time Indoors Increasing Owners Exposure to Allergens Like Pet Dander. earthbath’s Totally Natural ... , ... 26, 2010 -- Everyone wants to be inside when winter’s chilly winds blow, and Fido ...
... ... for physicians, including current and future adoption of electronic medical records, e-prescribing, ... ... are the physician specialist groups most likely to communicate with patients online, according ...
... SEATTLE , Jan. 26 Milliman Care Guidelines ... tools that help health plans, hospitals and other clients optimize ... and software.   , The Care Guidelines promote ... based on annually updated evidence, thus enabling informed and consistent ...
Cached Medicine News:Health News:Medical students may soon be tested on evolution 2Health News:Medical students may soon be tested on evolution 3Health News:End-of-life care strategies examined in Pennsylvania prisons 2Health News:Vancouver Company Must Meet Matt Lauer During Olympics 2Health News:Control Winter Pet Dander with earthbath's New Waterless Grooming Foam for Dogs 2Health News:Control Winter Pet Dander with earthbath's New Waterless Grooming Foam for Dogs 3Health News:Dermatologists, Medical Oncologists are the Top Physician Specialist Groups Communicating with Patients Online 2Health News:Dermatologists, Medical Oncologists are the Top Physician Specialist Groups Communicating with Patients Online 3Health News:Dermatologists, Medical Oncologists are the Top Physician Specialist Groups Communicating with Patients Online 4Health News:Milliman Care Guidelines Offers Online Interrater Reliability Tool and Training 2Health News:Milliman Care Guidelines Offers Online Interrater Reliability Tool and Training 3Health News:Milliman Care Guidelines Offers Online Interrater Reliability Tool and Training 4
Archimedes is an innovative specialty calculator. Forget having to remember complicated formulas, just enter the values and out come the results....
A handy, quick reference for physicians, nurses, and other health care providers treating cancer patients....
A handy quick-reference tool for busy residents and clinicians with key facts and points essential for day-to-day patient care....
Provides reliable information on the most commonly prescribed drugs, their side effects, interactions and cost of therapy....
Medicine Products: